Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.
Anthropocene Magazine13h
Increased access to medications may be a public health good—but it’s a big climate challenge
A massive global analysis reveals pharmaceuticals as the most carbon-intensive portion of the global health care system ...
Model Medicines Developing Drugs With AI: Vanguards of Health Care
We didn’t start Model to launch a company—we started it because no one else met our standards,” says Dr. Daniel Haders II, CEO and founder of Model Medicines. On this episode of Vanguards of Health ...